The fluorescent treponemal antibody absorption (FTA-ABS) double-staining (DS) test has been developed for microscopes equipped with incident illumination, and the procedure offers many advantages over the FTA-ABS test when tests are performed with this equipment. In The fluorescent treponemal antibody absorption (FTA-ABS) double-staining (DS) test (2, 3, 5, 6) has been reported as an alternative to the conventional FTA-ABS test for detecting treponemal antibody when incident-light microscopy is used. This procedure incorporates a rhodamine-labeled, class-specific, anti-human immunoglobulin G primary stain and fluorescein-labeled anti-treponemal globulin as counterstain. In this evaluation, we obtained 346 fresh sera and investigated the sensitivity and the specificity of the FTA-ABS DS test and the conventional FTA-ABS test. Primary parameters for this investigation included two microscopists with two microscope models and the new FTA-ABS DS test reporting system (3). The effects of sera heated at 56°C versus unheated sera and freezer storage were examined for some of the sera.
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MATERIALS AND METHODS
FTA-ABS test reagents and procedure. Treponema pallidum antigen, sorbent, control sera, and fluorescein-labeled anti-human globulin were reference reagents for the FTA-ABS test and were prepared by Biological Products Division at the Centers for Disease Control, Atlanta, Ga. The FTA-ABS test was performed according to the reference procedure in the Manual of Tests for Syphilis (7) .
FrA-ABS DS test reagents and procedure. T. pallidum antigen and sorbent were the same as the reference reagents for the FTA-ABS test. Reactive and nonspecific control sera and the fluorescein-labeled anti-treponemal globulin for counterstaining were as previously prepared for the FTA-ABS DS test procedure (2) . The primary stain, rhodamine-labeled F(ab')2 fragment of goat anti-human immunoglobulin G, was obtained commercially from Kallestad Laboratories, Chaska, Minn. The FTA-ABS DS test procedure was as described by Hunter et al. (3) Heated versus unheated sera. A sample of each of 166 sera was tested fresh (within 48 h) in the FTA-ABS DS test without heating along with a sample of the same serum that had been heated at 56°C for 30 min. These two FTA-ABS DS test results were compared with the FTA-ABS test results obtained with heated sera. The sera were read alternately by the two readers on their respective microscopes.
Freezer storage. Thirty-two sera that exhibited some degree of staining in the initial testing were retested after storage at -20°C for at least 2 weeks. Of these sera, 26 were from syphilitic individuals, and 8 of the 26 were read as B or Rl +. An equal number of sera, reactive and nonreactive, were also retested to doubleblind the second examination of the above sera. Specificity was determined by nonreactivity in nonsyphilitic sera. With the FTA-ABS DS test, 300 of 311 nonsyphilitic sera were nonreactive by the conventional reporting method, resulting in a specificity of 96%, whereas 305 of 311 sera were nonreactive by the DS reporting method, resulting in a specificity of 98%. For the FTA-ABS test, 290 of 311 sera were nonreactive, resulting in a specificity of 93%. Discrepancies were due primarily to the reporting of borderline sera. hanced by the incorporation of pure reagents, such as the F(ab')2 conjugate, in the FTA-ABS DS test as opposed to the whole globulin conjugate used in the reference FTA-ABS test. Likewise, we found little difference in results when sera frozen for at least 2 weeks were retested. The differences that did occur caused a slight drop in sensitivity and appeared to be related to individual sera rather than directly attributable to freezing, since the same sera had shifted in degrees of fluorescence throughout the evaluation. The FTA-ABS DS test is recommended as an acceptable confirmatory test for syphilis, along with the FTA-ABS test. Differences between the two tests were not great and, on the basis of our findings, we recommend the DS reporting procedure for both tests. The new DS reporting system (3) appears to deal more effectively with the problem of reporting borderlines.
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